BNIP3L

Across TCGA pan-cancer cohorts, BNIP3L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BNIP3L data layer compared with 20 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BNIP3L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BNIP3L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where BNIP3L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.201	0.870	<.001	34	view →
PDAC	DFS	Tertile	All	0.208	0.713	.004	22	view →
CCRCC	DFS	Tertile	All	0.823	0.610	.044	2	view →
LUAD	OS	Median	II,III,IV	0.871	0.449	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BNIP3L–LSCC (DFS)

Open the LSCC breakdown →